231 related articles for article (PubMed ID: 19499344)
1. Inhibitors of the FcRn:IgG protein-protein interaction.
Low SC; Mezo AR
AAPS J; 2009 Sep; 11(3):432-4. PubMed ID: 19499344
[TBL] [Abstract][Full Text] [Related]
2. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
3. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
4. Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction.
Wang Z; Fraley C; Mezo AR
Bioorg Med Chem Lett; 2013 Mar; 23(5):1253-6. PubMed ID: 23375228
[TBL] [Abstract][Full Text] [Related]
5. A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life.
Jensen PF; Schoch A; Larraillet V; Hilger M; Schlothauer T; Emrich T; Rand KD
Mol Cell Proteomics; 2017 Mar; 16(3):451-456. PubMed ID: 28062799
[TBL] [Abstract][Full Text] [Related]
6. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
7. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
Dall'Acqua WF; Kiener PA; Wu H
J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
[TBL] [Abstract][Full Text] [Related]
8. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
9. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
Patel DD; Bussel JB
J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
[TBL] [Abstract][Full Text] [Related]
10. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
[TBL] [Abstract][Full Text] [Related]
11. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.
Foss S; Grevys A; Sand KMK; Bern M; Blundell P; Michaelsen TE; Pleass RJ; Sandlie I; Andersen JT
J Control Release; 2016 Feb; 223():42-52. PubMed ID: 26718855
[TBL] [Abstract][Full Text] [Related]
12. The Dual Targeting of FcRn and FcγRs
Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
Front Immunol; 2021; 12():728322. PubMed ID: 34512662
[TBL] [Abstract][Full Text] [Related]
13. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
14. FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies.
Borghi S; Bournazos S; Thulin NK; Li C; Gajewski A; Sherwood RW; Zhang S; Harris E; Jagannathan P; Wang LX; Ravetch JV; Wang TT
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12943-12951. PubMed ID: 32461366
[TBL] [Abstract][Full Text] [Related]
15. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
16. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
17. Targeting FcRn for the modulation of antibody dynamics.
Ward ES; Devanaboyina SC; Ober RJ
Mol Immunol; 2015 Oct; 67(2 Pt A):131-41. PubMed ID: 25766596
[TBL] [Abstract][Full Text] [Related]
18. Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0.
Saxena A; Bai B; Hou SC; Jiang L; Ying T; Miersch S; Sidhu SS; Wu D
Methods Mol Biol; 2018; 1827():399-417. PubMed ID: 30196509
[TBL] [Abstract][Full Text] [Related]
19. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
20. Neonatal Fc receptor and IgG-based therapeutics.
Kuo TT; Aveson VG
MAbs; 2011; 3(5):422-30. PubMed ID: 22048693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
